Director, Vanguard Urologic Institute at MHMG
Urology
Dr. Kevin M. Slawin, MD
|
|
Give Review
Kevin M. Slawin, MD practices Urology. He attended Columbia University College of Physicians & Surgeons. Columbia University College of Physicians & Surgeons is a one of the best medicals schools. Columbia University College of Physicians & Surgeons is ranked 8/52 in Research/PrimaryCare. He received awards:"America's Top Doctors", "Top Doctors:SE Texas", "America's Top Doctors for Cancer" and "Meaningful Use Stage 1 Certification". Kevin Slawin is a published MD. He published 71 publications, including: 'The Prostate Health Index (phi) Selectively Identifies Clinically-Significant Prostate Cancer.' Kevin Slawin is registered with Medicare.
Publications
- The Prostate Health Index (phi) Selectively Identifies Clinically-Significant Prostate Cancer.
- Prospective Multicenter Evaluation of the Beckman Coulter Prostate Health Index Using WHO Calibration.
- A Multicenter Study of [-2]Pro-Prostate Specific Antigen Combined With Prostate Specific Antigen and Free Prostate Specific Antigen for Prostate Cancer Detection in th...
- The phosphatase SRC homology region 2 domain-containing phosphatase-1 is an intrinsic central regulator of dendritic cell function.
- A composite MyD88/CD40 switch synergistically activates mouse and human dendritic cells for enhanced antitumor efficacy.
- Emerging vaccine therapy approaches for prostate Cancer.
- Pre-treatment biomarker levels improve the accuracy of post-Prostatectomy nomogram for prediction of biochemical recurrence.
- A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3-4N0 prostate Cancer.
- Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative Blood-based biomarkers.
- Preoperative plasma endoglin levels predict biochemical progression after radical Prostatectomy.
- Use of preoperative plasma endoglin for prediction of lymph node metastasis in patients with clinically localized prostate Cancer.
- Potentially harmful effect of a testosterone dietary supplement on prostate Cancer growth and metastasis.
- Herbal/hormonal dietary supplement possibly associated with prostate Cancer progression.
- Enhanced activation of human dendritic cells by inducible CD40 and Toll-like receptor-4 ligation.
- Vaccine therapy for prostate Cancer.
- Prognostic significance of location of positive margins in radical Prostatectomy specimens.
- Plasminogen activation inhibitor-1 improves the predictive accuracy of prostate Cancer nomograms.
- Preoperative plasma HER2 and epidermal growth factor receptor for staging and prognostication in patients with clinically localized prostate Cancer.
- Prostate-specific antigen and Prostate-specific antigen derivatives as predictors of benign prostatic hyperplasia progression.
- Predicting the outcome of salvage radiation therapy for recurrent prostate Cancer after radical prostatectomy.
- Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate Cancer and invasion, progression, and metastasis.
- An essential role for Akt1 in dendritic cell function and tumor immunotherapy.
- Prognostic indicators for disease progression following radical Prostatectomy.
- Newer modalities of ultrasound imaging and treatment of the Prostate.
- Development of nomogram to predict acute Urinary retention or surgical intervention, with or without dutasteride therapy, in men with benign prostatic hyperplasia.
- Pilot study of radiofrequency interstitial tumor ablation (RITA) for the treatment of radio-recurrent prostate Cancer.
- Expression of survivin and apoptotic biomarkers in benign prostatic hyperplasia.
- Versatile prostate Cancer treatment with inducible caspase and interleukin-12.
- Re-engineered CD40 receptor enables potent pharmacological activation of dendritic-cell Cancer vaccines in vivo.
- Reliability of remembered International Index of Erectile Function domain scores in men with localized prostate Cancer.
- Anomalies of the wolffian duct derivatives encountered at radical Prostatectomy.
- BPSA: A Novel Serum Marker for Benign Prostatic Hyperplasia.
- The value of radiotherapy in treating recurrent prostate Cancer after radical prostatectomy.
- Effects of systematic 12-core biopsy on the performance of percent free prostate specific antigen for prostate Cancer detection.
- Is tumor volume an independent prognostic factor in clinically localized prostate Cancer?
- Variation in prostate specific antigen results from 2 different assay platforms: clinical impact on 2304 patients undergoing prostate Cancer screening.
- Molecular diagnosis of prostate Cancer.
- Impact of unilateral interposition sural nerve grafting on recovery of urinary function after radical Prostatectomy.
- Tissue expression of transforming growth factor-beta1 and its receptors: correlation with pathologic features and biochemical progression in patients undergoing radica...
- Predicting the presence and side of extracapsular extension: a nomogram for staging prostate Cancer.
- Predictors of prostate Cancer after initial negative systematic 12 core biopsy.
- Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate Cancer.
- Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical pr...
- Salvage radiotherapy for recurrent prostate Cancer after radical prostatectomy.
- Association of pre- and postoperative plasma levels of transforming growth factor beta(1) and interleukin 6 and its soluble receptor with prostate Cancer progression.
- Improved detection of clinically significant, curable prostate Cancer with systematic 12-core biopsy.
- The EZC-Prostate model: noninvasive Prostate imaging in living mice.
- Survivin expression is associated with features of biologically aggressive Prostate carcinoma.
- Six additional systematic lateral cores enhance sextant biopsy prediction of pathological features at radical Prostatectomy.
- Minimally Invasive Therapy for Prostate Cancer: Use of Nomograms to Counsel Patients about the Choice and Probable Outcome of Therapy.
- The Use of Nomograms for Selecting BPH Candidates for Dutasteride Therapy.
- Beyond prostate-specific antigen: new serologic biomarkers for improved diagnosis and management of prostate Cancer.
- Rising Prostate-specific antigen level after Prostatectomy.
- Preoperative plasma soluble E-cadherin predicts metastases to lymph nodes and prognosis in patients undergoing radical cystectomy.
- Counseling men with prostate Cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors.
- The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients...
- Early postoperative peripheral blood reverse transcription PCR assay for prostate-specific antigen is associated with prostate Cancer progression in patients undergoin...
- Comparison of immunohistochemistry with reverse transcription-PCR for the detection of micrometastatic prostate Cancer in lymph nodes.
- Biochemical staging of prostate Cancer.
- Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carci...
- Detection of clinically significant, occult prostate Cancer metastases in lymph nodes using a splice variant-specific rt-PCR assay for human glandular kallikrein.
- Correlation of preoperative levels of IGF-I and IGFBP-3 with pathologic parameters and clinical outcome in patients with Bladder cancer.
- The medical therapy of prostatic symptoms study: what will we learn?
- Peripheral blood rt-PCR assays for detection and prognosis of prostate Cancer.
- Preoperative blood reverse transcriptase-PCR assays for prostate-specific antigen and human glandular kallikrein for prediction of prostate Cancer progression after ra...
- Preoperative plasma levels of interleukin-6 and its soluble receptor predict disease recurrence and survival of patients with Bladder cancer.
- Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and -3 with prostate Cancer invasion, progr...
- Early management of prostate Cancer: how to respond to an elevated PSA?
- Sural Nerve Interposition Grafting during Radical Prostatectomy.
- Radiation therapy after radical Prostatectomy: why patience is a virtue! The case for salvage radiation therapy.
Procedures Preformed
- Cystometry
- Cystotomy
- Cystourethroplasty with Repair of Bladder Neck with Robotic Assistance
- Cystourethroscopy and Transurethral Resection of Bladder Neck
- View All
Conditions Treated
- Bladder Cancer
- Bladder Infection
- Bladder Stones
- Blood in Urine (Hematuria)
- View All
Doctors Specialties
- Urology
Accepted Insurances
Awards
- America's Top Doctors
- Top Doctors:SE Texas
- America's Top Doctors for Cancer
- Meaningful Use Stage 1 Certification
Education
-
Baylor College of Medicine -
New York Presbyterian Hospital - Columbia Campus -
Mount Sinai School of Medicine -
Columbia University College of Physicians & Surgeons
Hospital
-
Texas Children's Hospital -
Baylor St. Luke's Medical Center
Drug Facts
| NPI NUMBER | 1235162884 | |
| NPPES Provider LastName | SLAWIN | |
| NPPES Provider FirstName | KEVIN | |
| NPPES Provider ZIPCode | 770301521 | |
| NPPES Provider State | TX | |
| Specialty Description | Urology | |
| Total Claim Count | 497.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1235162884 |
| Last Name Of The Provider | SLAWIN |
| First Name Of The Provider | KEVIN |
| View All |
Similar Doctors
|
Dr. Omar H. Durrani, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Ori Hampel, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Wesley Ekeruo, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Larry I. Lipshultz, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Mohit Khera, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Mark D. Kalish, MD |
|
|
Dr. Edward Schatte, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gilad E. Amiel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John S. Colen, MD |
|
|
Dr. Paul C. Cook, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mehrad Adibi, MD |
|
|
Dr. Alexander W. Jule, MD |
|
|
Dr. Melina J. McCarty, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ross E. Krasnow, MD |
|
|
Dr. Clark A. Wilson, MD |